Achaogen Inc: Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Opened Position

January 10, 2018 - By Clifton Ray

 Achaogen Inc: Julian Baker And Felix Baker's Baker Bros. Advisors Lp Opened Position

Investors sentiment decreased to 1.16 in Q3 2017. Its down 1.22, from 2.38 in 2017Q2. It is negative, as 23 investors sold Achaogen, Inc. shares while 20 reduced holdings. 14 funds opened positions while 36 raised stakes. 31.77 million shares or 0.83% less from 32.03 million shares in 2017Q2 were reported.

Goldman Sachs holds 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 321,772 shares. Switzerland-based Credit Suisse Ag has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Citadel Advisors Limited Liability holds 0.01% in Achaogen, Inc. (NASDAQ:AKAO) or 736,089 shares. Iconiq Capital Limited Liability Corp reported 0.05% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO). Geode Cap Management Limited Liability Company holds 0% or 293,612 shares in its portfolio. State Board Of Administration Of Florida Retirement System has 16,486 shares for 0% of their portfolio. Hikari Ltd accumulated 30,000 shares or 0.06% of the stock. Harbourvest Partners Ltd Liability Company holds 20,000 shares. Royal Bancshares Of Canada holds 0% or 3,491 shares. Ontario – Canada-based Fincl Bank Of Montreal Can has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Fiera Capital Corporation has invested 0.02% in Achaogen, Inc. (NASDAQ:AKAO). Legal And General Group Public Limited Liability Company has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Swiss Bancorp has invested 0% in Achaogen, Inc. (NASDAQ:AKAO). Renaissance Technologies Llc stated it has 18,800 shares. Weiss Multi reported 35,500 shares or 0.02% of all its holdings.

Since September 26, 2017, it had 2 insider buys, and 2 selling transactions for $1.72 million activity. Another trade for 1,146 shares valued at $18,325 was made by LOEB GARY on Tuesday, September 26. Wise Blake sold 3,576 shares worth $57,180.

The New Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Holding in Achaogen Inc

Baker Bros. Advisors Lp reported SC 13G/A form with the SEC for Achaogen Inc. Access it here: 000114420418001709. As reported by Julian Baker And Felix Baker’s Baker Bros. Advisors Lp, the filler owns 0.3% or 122,482 shares of the Health Care–company.

Achaogen Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s positive view for Achaogen Inc. For a hedge fund managing $8.20 billion in assets and having 25+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s portfolio is in the sector.

Achaogen Inc Institutional Sentiment

Filings show 35 investors own Achaogen Inc. The ownership in Q3 2015 is low, at Infinity of the outstanding shares. This is increased by 5566635. 13318263 were owned by these investors. 6 funds opened new Achaogen Inc stakes, 10 increased positions. There were 15 that closed positions and 10 reduced them.

Iconiq Capital Llc is an investor bullish on Achaogen Inc, owning 14296 shares as of Q3 2015 for 0.02% of its portfolio. Wellcome Trust Ltd owns 1125616 shares or 0.14% of its portfolio. OR Mazama Capital Management Inc have 1.60% of its portfolio for 1341078 shares. Further, Murphy Michael R reported stake worth 1.76% of its portfolio. The NY New Leaf Venture Partners Llc owns 132728 shares. Achaogen Inc is 0.66% of its portfolio.

SEC Form 13G.

Analysts await Achaogen, Inc. (NASDAQ:AKAO) to report earnings on March, 13. They expect $-0.79 EPS, up 24.04 % or $0.25 from last year’s $-1.04 per share. After $-0.85 actual EPS reported by Achaogen, Inc. for the previous quarter, Wall Street now forecasts -7.06 % EPS growth.

The stock increased 4.57% or $0.51 during the last trading session, reaching $11.66. About 1.10M shares traded or 6.37% up from the average. Achaogen, Inc. (NASDAQ:AKAO) has risen 757.99% since January 10, 2017 and is uptrending. It has outperformed by 741.29% the S&P500.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $494.31 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Achaogen, Inc. (NASDAQ:AKAO) Ratings Coverage

Among 10 analysts covering Achaogen (NASDAQ:AKAO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Achaogen has $3100 highest and $9 lowest target. $23’s average target is 97.26% above currents $11.66 stock price. Achaogen had 21 analyst reports since March 16, 2016 according to SRatingsIntel. Needham downgraded Achaogen, Inc. (NASDAQ:AKAO) on Wednesday, March 16 to “Hold” rating. Stifel Nicolaus maintained Achaogen, Inc. (NASDAQ:AKAO) rating on Thursday, November 9. Stifel Nicolaus has “Buy” rating and $27.0 target. The stock of Achaogen, Inc. (NASDAQ:AKAO) has “Outperform” rating given on Wednesday, January 4 by Leerink Swann. Cowen & Co maintained Achaogen, Inc. (NASDAQ:AKAO) on Thursday, June 1 with “Buy” rating. Cowen & Co maintained Achaogen, Inc. (NASDAQ:AKAO) on Tuesday, January 2 with “Buy” rating. As per Thursday, August 3, the company rating was maintained by Stifel Nicolaus. The firm has “Outperform” rating by Leerink Swann given on Monday, October 9. The rating was initiated by Stifel Nicolaus on Tuesday, February 7 with “Buy”. The firm has “Buy” rating given on Friday, September 15 by Needham. Needham upgraded it to “Buy” rating and $19 target in Tuesday, December 13 report.

More recent Achaogen, Inc. (NASDAQ:AKAO) news were published by: which released: “Achaogen Announces FDA Acceptance of New Drug Application with Priority Review …” on January 02, 2018. Also published the news titled: “Achaogen Appoints Blake Wise Chief Executive Officer” on December 11, 2017.‘s news article titled: “Achaogen to Present at JP Morgan Healthcare Conference” with publication date: January 03, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.